Pharmalucence Builds New Drug Production Facility in Massachusetts
06/04/2010
"Pharmalucence has long maintained a strong radiopharmaceutical business in Massachusetts," said Glenn Alto, president and CEO of Pharmalucence. "We are investing to fully replace and modernize our infrastructure to ensure we maintain our local presence going forward."
The investment was aided by a $20 million bond issued by MassDevelopment, the first use of the Recovery Zone Facility Bond program in the state. The bond is one component of the American Recovery and Reinvestment Act to stimulate the economy with low-cost financing.
Pharmalucence produces eight drugs to treat cancers and heart disease. Construction on the new facility will begin this summer, and the plant is expected to be operational by the end of 2012.
Project Announcements
NSP Panels Establishes Mullins, South Carolina, Manufacturing Operations
03/25/2026
United Composite Materials Plans Greenville County, South Carolina, Manufacturing Operations
03/25/2026
Van-Am Expands St. Joseph, Missouri, Operations
03/25/2026
Lufburrow & Company Plans Aberdeen, Maryland, Manufacturing Operations
03/24/2026
Autokiniton Expands Bellevue, Ohio, Manufacturing Operations
03/24/2026
Philip Morris International Plans Tampa, Florida, Operations
03/24/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
The Geography of Packaging: Why Location Strategy Matters More Than Ever
Q1 2026